Literature DB >> 30651253

Lesson of the month 1: Prolonged QT syndrome due to donepezil: a reversible cause of falls?

Emily G Jackson1, Sarah Stowe2.   

Abstract

Prolonged QT syndrome precipitates cardiac arrhythmias such as torsades de pointes (TdP) resulting in cardiogenic syncope or sudden death. We report a case of prolonged QT syndrome caused by donepezil which resulted in a fall and hip fracture. In this case female sex, advanced age and diuretic use may have increased the risk of recurrent syncope and potential underlying TdP. Cessation of donepezil resulted in normalisation of the QT interval. This case highlights a lesser known side effect of this dementia drug. It also reminds us of the importance of taking a thorough drug history while considering potential drug toxicity/interactions as part of the comprehensive geriatric assessment. © Royal College of Physicians 2019. All rights reserved.

Entities:  

Keywords:  Donepezil; QT interval; falls; syncope; torsades de pointes

Year:  2019        PMID: 30651253      PMCID: PMC6399646          DOI: 10.7861/clinmedicine.19-1-80

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  7 in total

Review 1.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology.

Authors:  Pentti M Rautaharju; Borys Surawicz; Leonard S Gettes; James J Bailey; Rory Childers; Barbara J Deal; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Gerard van Herpen; Galen S Wagner; Hein Wellens
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 24.094

2.  A case of donepezil-related torsades de pointes.

Authors:  Jamie Kitt; Robert Irons; Mohamed Al-Obaidi; Constantinos Missouris
Journal:  BMJ Case Rep       Date:  2015-10-05

3.  Torsades de Pointes with QT prolongation related to donepezil use.

Authors:  Tomofumi Takaya; Masashi Okamoto; Keiko Yodoi; Katsuya Hata; Yoichi Kijima; Hideto Nakajima; Yuji Nishikawa; Tomoyuki Kita; Mitsuaki Ito; Toshihiko Seo; Seinosuke Kawashima
Journal:  J Cardiol       Date:  2009-05-07       Impact factor: 3.159

Review 4.  Drug-induced QT interval prolongation: mechanisms and clinical management.

Authors:  Senthil Nachimuthu; Manish D Assar; Jeffrey M Schussler
Journal:  Ther Adv Drug Saf       Date:  2012-10

5.  Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

Authors:  Dae Hyun Kim; Rebecca T Brown; Eric L Ding; Douglas P Kiel; Sarah D Berry
Journal:  J Am Geriatr Soc       Date:  2011-06-07       Impact factor: 5.562

Review 6.  Donepezil for dementia due to Alzheimer's disease.

Authors:  Jacqueline S Birks; Richard J Harvey
Journal:  Cochrane Database Syst Rev       Date:  2018-06-18

7.  Incidence and prediction of falls in dementia: a prospective study in older people.

Authors:  Louise M Allan; Clive G Ballard; Elise N Rowan; Rose Anne Kenny
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

  7 in total
  3 in total

1.  Donepezil - QT prolongation and torsades de pointes.

Authors:  Bilal Haider Malik
Journal:  Clin Med (Lond)       Date:  2019-03       Impact factor: 2.659

2.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

Review 3.  Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon.

Authors:  Bilal Haider Malik; Pousette Hamid; Safeera Khan; Deepti Gupta; Muhammad Islam
Journal:  Cureus       Date:  2019-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.